Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;10(10):922-30.
doi: 10.1016/S1474-4422(11)70187-9.

Management of refractory status epilepticus in adults: still more questions than answers

Affiliations
Review

Management of refractory status epilepticus in adults: still more questions than answers

Andrea O Rossetti et al. Lancet Neurol. 2011 Oct.

Abstract

Refractory status epilepticus (RSE) is defined as status epilepticus that continues despite treatment with benzodiazepines and one antiepileptic drug. RSE should be treated promptly to prevent morbidity and mortality; however, scarce evidence is available to support the choice of specific treatments. Major independent outcome predictors are age (not modifiable) and cause (which should be actively targeted). Recent recommendations for adults suggest that the aggressiveness of treatment for RSE should be tailored to the clinical situation. To minimise intensive care unit-related complications, focal RSE without impairment of consciousness might initially be approached conservatively; conversely, early induction of pharmacological coma is advisable in generalised convulsive forms of the disorder. At this stage, midazolam, propofol, or barbiturates are the most commonly used drugs. Several other treatments, such as additional anaesthetics, other antiepileptic or immunomodulatory compounds, or non-pharmacological approaches (eg, electroconvulsive treatment or hypothermia), have been used in protracted RSE. Treatment lasting weeks or months can sometimes result in a good outcome, as in selected patients after encephalitis or autoimmune disorders. Well designed prospective studies of RSE are urgently needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of status epilepticus treatment*. Increasing refractoriness is illustrated by the background color intensity; the non-sedating agents are green, anesthetics in orange to red, and other options in yellow or white. First-line treatment is light green, second-line darker green, and third line light and darker orange. Other options are given in red, yellow and blue. *Great caution is required for valproate in children under 2 years (hepatic toxicity), and propofol in young children (propofol infusion syndrome). In this setting, benzodiazepines, phenytoin and barbiturates represent the most widely used options. CLZ: clonazepam; ECT: electroconvulsive treatment; KD: ketogenic diet; LCM: lacosamide; LEV: levetiracetam; LZP: lorazepam; MDZ: midazolam; PGB: pregabaline; PHT: phenytoin; PRO: propofol; PTB: pentobarbital; rTMS: repetitive transcranial magnetic stimulation; SE: status epilepticus; THP: thiopental; TPM: topiramate; VNS: vagus nerve stimulation; VPA: valproate.

References

    1. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR) Neurology. 2000;55(5):693–7. - PubMed
    1. DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–35. - PubMed
    1. Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714–8. - PubMed
    1. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970–6. - PubMed
    1. Holtkamp M. Treatment strategies for refractory status epilepticus. Curr Opin Crit Care. 2011;17(2):94–100. - PubMed

Publication types